Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company that offers next-generation radiopharmaceutical medicines for cancer treatments. It has developed targeted alpha therapies (TATs) with its Fast-Clear linker technology that connects alpha medical isotopes to antibodies and targeting molecules, inducing cancer cell death. The company has a pipeline of programs that includes FPI-1434, FPI-1966, FPI-2059 and FPI-1434 combination therapies, which are candidates for treating solid tumors, and head and neck, and bladder cancers. Headquartered in Hamilton, Canada, Fusion Pharmaceuticals is publicly held with an office in the US.